[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seizures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seizures":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,43,65,102,130,161,215,239,265,312,340,367,389,414,463,487,513,541,575,595,620,661,687,710,733],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100317946","electrographic-seizure-management-and-neurobehavioral-outcomes-in-critically-ill-children-100317946",false,"NCT03419260","Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children","Inclusion Criteria:\n\n1. Care in the Children's Hospital of Philadelphia Pediatric ICU.\n2. Clinically indicated continuous EEG monitoring.\n3. Age \\> 1 month to 18 years.\n\nExclusion Criteria:\n\n1. Admitted for Phase 2 (intracranial) EEG monitoring.\n2. Intensivist expects to discontinue technological support in the next two days given underlying medical or neurological problems.","ALL","1 Month","18 Years",{"count":20,"type":21},2500,"ESTIMATED","OBSERVATIONAL","Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies.\n\nThis is a single-center prospective observational study. The investigators aim to: (1) track critically ill patients undergoing clinically indicated EEG monitoring and seizure management to identify risk factors for electrographic seizures, (2) create prediction models guiding EEG monitoring resources to the patients at highest risk for seizures, and (3) evaluate our current management strategy in terms of safety.",[25],"Seizures",[27,28,29],"seizures","status epilepticus","EEG monitoring","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":34},"2017-03-13",{"date":38,"type":21},"2028-01-01",{"name":40,"class":41},"Children's Hospital of Philadelphia","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100450036","de-identified-unmh-eeg-corpus-database-creation-with-fully-de-identified-clinical-information-100450036","NCT05140265","De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","The Creation of a Pilot Database of EEG Recordings and de- Identified Medical Records From Patients Internally Referred Within the UNMH Comprehensive Epilepsy Center","Inclusion Criteria:\n\n* We will screen with UNMH EEG database, Nihon Kohden Neuroworkbench first. After meeting all the inclusion and exclusion criteria, we will access the Cerner Powerchart (UNMH EMR) for the rest of the clinical information.\n* 18 years old or older. If the patient's age is over 89, we will aggregated them to age 90 or older so that the patient cannot be identified. Also, all the EEG data will be de-identified and only show the year of the study performed instead of the exact study date to reduce the risk of identification. Of note, we perform over few thousands of EEG studies per year and it will be almost impossible to identify the patient based on the study year.\n\nExclusion Criteria:\n\n* Children under age of 18 years old will be excluded.\n* Mismatched patients between EEG database and EMR",{"count":51,"type":21},20000,"This proposal outlines the steps required for the creation of a pilot database of EEG recordings and de-identified medical records from patients internally referred within the UNMH Comprehensive Epilepsy Center. The UNMH EEG Corpus would be the first database of its kind. Other public databases contain either patient EEG signals or medical records, but without both kinds of information, it is impossible to relate pre-treatment neurobiomarkers with post-treatment prognosis. The database will also contain information that can improve seizure localization based off of scalp and intracranial EEG, and the requisite data for the creation of algorithms that forecast seizure activity; a development that could ultimately lead to novel responsive neural stimulation procedures that suppress seizures before they begin.",[54,55,25],"Epilepsy","Status Epilepticus","2026-06-17",{"date":58,"type":34},"2026-06-22",{"date":60,"type":34},"2021-10-11",{"date":62,"type":21},"2030-12-31",{"name":64,"class":41},"University of New Mexico",{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100557160","phase-4-study-of-the-pharmacokinetics-safety-and-tolerability-of-zonisade-in-children-1-month-to-17-years-of-age-with-partial-onset-seizures-100557160","NCT06534502","Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg\u002F5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures","Inclusion Criteria:\n\n* Pediatric participants (ages 1 month to 17 years of age, inclusive) will be considered eligible for the study based on the following criteria:\n\n  1. Voluntarily obtained informed consent from parent\u002Flegal guardian of the participant and assent from the participant, when appropriate.\n  2. Willing and able to follow protocol specific requirements.\n  3. Participant of 1 month to 17 years of age, inclusive (at time of consent).\n  4. Participant diagnosed with partial-onset (focal) seizures, with or without secondary generalization as per current International League Against Epilepsy (ILAE) classification of seizures. Participants with both focal-onset and generalized-onset seizures are eligible, but only focal-onset seizures count toward baseline seizure enrollment criteria. Tonic-clonic and tonic seizures with unknown onset are presumed to be focal-onset unless there are clear clinical and EEG data suggesting generalized-onset.\n  5. Participant with seizure occurrence more than once in the past three (3) months and more than two (2) times in the past six (6) months.\n\n     a. Participant who is 6 months of age and younger will have seizure profiling patterns assessed by the Investigator for appropriate consideration and inclusion in the study.\n  6. Participant on a stable regimen of anti-epilepsy drugs (AEDs) for at least 30 days before screening\n\n     a. Participant who is 6 months of age and younger will have regimen assessed for inclusion in the study at Investigator's discretion.\n  7. Participant with acceptable laboratory investigations:\n\n     1. Hemoglobin within normal range\n     2. Alanine aminotransferase (ALT) within normal range\n     3. Aspartate aminotransferase (AST) up to 1.5 x upper limit of normal (ULN)\n     4. Bilirubin within normal range\n     5. Creatinine clearance within normal range\n  8. If male participant is able to father children must be willing to use a highly effective method of contraception for at least one month after the last dose of investigational product if at risk of pregnancy with her\u002Fhis partner. If female participant has reached menarche, the participant is authorized to participate in this clinical study if additional criteria are met.\n\nAt screening:\n\n1. (i) Participant reports sexual abstinence for the prior 3 months or reports use of at least 1 of the acceptable methods of contraception, including an intrauterine device, barrier methods (e.g., male or female condom), hormonal contraceptives (e.g., hormonal patches, vaginal devices, oral pills), levonorgestrel intrauterine system (e.g., Mirena®), or regular medroxyprogesterone injections (e.g., Depo-Provera®); or (ii) Participant agrees to initiate sexual abstinence from the time of screening until at least one month after end of treatment with study drug; and\n2. Participant is advised to avoid conception from the time of screening until at least one month after last receipt of study drug and agrees not to attempt pregnancy from the time of screening until at least one month after end of treatment with study drug; and\n3. Participant is provided guidelines regarding continuation of abstinence, initiation of abstinence, or about allowed contraception; and\n4. Participant has a negative serum β-human chorionic gonadotropin (β-hCG) test just prior to study entry. Since serum tests may miss an early pregnancy, relevant menstrual history and sexual history, including methods of contraception, should be considered. Note: if the result of the serum β-hCG test cannot be obtained prior to dosing of investigational product, a participant may be enrolled on the basis of a negative urine pregnancy test, though a serum β-hCG test result must still be obtained.\n\nExclusion Criteria:\n\n* Pediatric participant will be excluded from the study based on the following criteria:\n\n  1. Known hypersensitivity to zonisamide or to any component of the investigational product or to sulfonamides.\n  2. Participant who is pregnant or nursing.\n  3. Participant with exclusively generalized-onset seizures.\n  4. Participant with predisposition to nephrolithiasis or prior history of kidney stone(s).\n  5. Participant who is underweight (weight-for-age \\\u003C2 standard deviation (SD) from the median of the World Health Organization (WHO) Child Growth Standards) or have a decreased appetite.\n  6. Participant currently on or scheduled to receive carbonic anhydrase inhibitors such as topiramate or acetazolamide.\n  7. Participant currently on or are scheduled to receive drugs known to have pharmacokinetic (PK) interaction.\n  8. Participant who has previously received zonisamide.\n  9. Participant with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).\n  10. Participant who has degenerative or metabolic disease of the brain.\n  11. Participant with history of psychiatric disorder (excluding stable attention deficit hyperactivity disorder (ADHD), mood disorder on adequate treatment).\n  12. Participant has any condition which, in the Investigator's opinion, would make it unsafe for the participant to participate in this study.\n  13. Participant who has participated in other clinical study 30 days prior to enrollment in this study or 4-5 half lives of investigational drug, whichever is longer.\n  14. Participant who uses alcohol or is currently on or scheduled to receive other central nervous system (CNS) depressants.\n  15. Participant has a positive COVID-19 polymerase chain reaction (PCR) test result; or has had exposure (within 2 weeks prior to screening) to someone who had a positive COVID-19 test result; or is suspected of having long COVID-19 by the Investigator or designee.\n  16. Participant who is missing more than 15% of daily diary entries during the screening period.","17 Years",{"count":74,"type":21},40,"INTERVENTIONAL",[77],"PHASE4","The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).",[25,80,81,82,83,84,54],"Seizures, Focal","Seizure, Partial Onset","Seizure Disorder, Partial","Seizure, Partial","Epilepsies, Partial",[86,87,88,89],"Partial-onset (focal) seizures","Pediatrics","ZONISADE","Zonisamide","NOT_YET_RECRUITING","2026-06-02",{"date":93,"type":34},"2026-06-04",{"date":95,"type":21},"2026-09",{"date":97,"type":21},"2027-09",{"name":99,"class":100},"Azurity Pharmaceuticals","INDUSTRY",2,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100322511","investigating-epilepsy-screening-and-evaluation-100322511","NCT03478852","Investigating Epilepsy: Screening and Evaluation","* INCLUSION CRITERIA:\n* Age 8 years or older\n* Known or suspected diagnosis of epilepsy\n* Ability to give informed consent or have a legally authorized representative able to give consent (for adults without consent capacity) or parent\u002Fguardian able to provide informed consent (for a child)\n* If unable to give informed consent, ability to give verbal assent\n\nEXCLUSION CRITERIA:\n\n* Patients with unstable medical conditions that, in the opinion of the investigators, makes participation unsafe, or who, in the opinion of the investigators may be unable to comply with the protocol\n* Patients who are unable to travel to the NIH","8 Years","110 Years",{"count":111,"type":21},1000,"Background:\n\nEpilepsy affects about 1 percent of the U.S. population. Most people with epilepsy respond well to medicine, but some do not. Researchers want people who have diagnosed or suspected epilepsy to participate in ongoing studies. They want to learn more about clinical care for epilepsy. They want fellows and residents to learn more about the care of people with epilepsy.\n\nObjectives:\n\nTo learn more about seizures and find ways to best treat people with drug-resistant epilepsy.\n\nEligibility:\n\nAdults and children ages 8 years and older with diagnosed or suspected epilepsy\n\nDesign:\n\nParticipants will be screened with:\n\nPhysical exam\n\nMedical history\n\nQuestionnaires\n\nParticipants will have many visits. They may be admitted to the hospital for several weeks. Their medication might be stopped or changed.\n\nParticipants will have many tests:\n\nBlood and urine tests\n\nEEG: Wires attached to the head with paste record brain waves. This may be videotaped.\n\nThinking and memory tests\n\nMRI: Participants lie on a table that slides in and out of a tube. They perform simple tasks in the tube.\n\nMEG: Participants lie on a table and place their head in a helmet to record brain waves.\n\nPET scan: Participants lie on a table that slides into a machine. A small amount of radioactive dye is injected into their arm with an IV. For the IV, a small tube is inserted into the arm with a needle.\n\nParticipants will stay enrolled in this study if they join other epilepsy-related studies. They may be contacted at intervals for follow-up. Their participation will end if they have not been seen clinically for their epilepsy for 3 years.",[25,54,114,115],"Epilepsy, Temporal Lobe","Partial Epilepsy",[117,25,118,119,120],"Seizure Disorder","Antiepileptic Drug","Natural History Study","Screening Protocol",{"date":122,"type":34},"2026-06-03",{"date":124,"type":34},"2018-03-28",{"date":126,"type":21},"2027-07-30",{"name":128,"class":129},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":75,"phases":141,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":42},"100610496","early-phase-1-cholinergic-enhancement-of-theta-100610496","NCT07228338","Cholinergic Enhancement of Theta","Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity","Inclusion Criteria:\n\n1. Age 18 - 75 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n\nExclusion Criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.\n3. Hepatic impairment (moderate or severe).\n4. Renal impairment (moderate or severe).\n5. Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.\n6. History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).\n7. Untreated narrow-angle glaucoma.\n8. Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).\n9. Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.\n10. Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.\n11. Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.\n12. Drugs Eliminated by Active Tubular Secretion.\n13. Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.",true,"75 Years",{"count":140,"type":21},50,[142],"EARLY_PHASE1","The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and\u002For associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.",[54,25,145,146,147],"Cognitive Impairment, Mild","Memory Disorder","Memory Loss",[149,150,151],"oscillatory changest","cholinergic agonist","muscarinic agonist","2026-04-08",{"date":154,"type":34},"2026-04-09",{"date":156,"type":21},"2026-10",{"date":158,"type":21},"2031-10",{"name":160,"class":41},"University of Texas Southwestern Medical Center",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":75,"phases":170,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100602997","phase-2-prophylactic-anti-seizure-medication-vs-no-anti-seizure-medication-for-patients-with-primary-motor-cortex-brain-metastases-100602997","NCT07130786","Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases","A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex","Inclusion Criteria:\n\n1. Participants must have a biopsy proven solid malignancy with at least one intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis located in the primary motor cortex measuring 0.5 cm or larger in maximal unidimensional size\n2. Age of at least 18 years\n3. Karnofsky performance status of at least 60\n4. Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and\u002For study PI\n5. Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF\u002FHCC approved eConsent medium\n\nExclusion Criteria:\n\n1. Participants with prior seizures as this is a study for seizure naïve patients\n2. Participants with an allergy to levetiracetam as levetiracetam is the prophylactic anti-seizure medication under study\n3. Participants concurrently taking (i.e. at enrollment) an ASM for non-seizure indications at clinically relevant doses (gabapentin 1800 mg\u002Fday or higher, pregabalin 300 mg\u002F day or higher, lamotrigine 150 mg\u002F day or higher, valproic acid 1000 mg\u002F day or higher, topiramate 200 mg\u002F day or higher, carbamazepine 200 mg\u002F day or higher, oxcarbazepine 300 mg\u002F day or higher, primidone 100 mg\u002Fday or higher) because use of these medications could bias the study toward the null\n4. Participants who cannot tolerate a magnetic resonance imaging (MRI) study of the brain, which is required to determine the presence of and follow the course of brain metastases under study\n5. Participants who cannot receive gadolinium as MRI of the brain with contrast is required\n6. Participants with end stage renal disease due to risk of nephrogenic systemic fibrosis in this patient population after exposure to gadolinium-based contrast agents\n7. Participants with widespread, definitive leptomeningeal disease given that leptomeningeal disease and brain metastases are different entities\n8. Pregnant women are excluded from this study because levetiracetam crosses the placenta. In addition, the potential deleterious effects of gadolinium on the developing fetus are not completely known\n9. Women who are breastfeeding are excluded from this study because levetiracetam enters breast milk. In addition, the potential deleterious effects of gadolinium in breast milk remain unknown",{"count":169,"type":21},150,[171],"PHASE2","This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.",[25,174,175,176,177],"Primary Motor Cortex","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Brain Metastases, Adult","Brain Metastases From Extra-cranial Solid Tumors",[179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205],"brain metastases","seizure","levetiracetam","seizure-naive","keppra","motor","primary motor cortex","motor strip","prophylaxis","Anti-Seizure Medication","ASM","SRS","SRT","necrosis","local recurrence","quality of life","focal aware","focal impaired awareness","focal to bilateral tonic clonic","generalized","focal preserved consciousness","focal impaired consciousness","FPC","FIC","FTBC","tonic","clonic","2026-03-17",{"date":208,"type":34},"2026-03-19",{"date":210,"type":34},"2025-12-23",{"date":212,"type":21},"2030-02",{"name":214,"class":41},"Ayal A. Aizer, MD",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":42},"100348895","etiology-and-treatment-of-neonatal-seizure-100348895","NCT03822741","Etiology and Treatment of Neonatal Seizure","Gene Profiling and Individualized Treatment of Neonatal Seizure in China","Inclusion Criteria:\n\n* severe seizures in neonates or generalized epilepsy or intractable epilepsy in infancy with generalized tonic-clonic seizures,\n* seizures onset before 1 year of age,\n* epileptic syndromes\u002Fepileptic-encephalopathies with unknown etiology.\n\nExclusion Criteria:\n\n* Patients were excluded if they had traumas, central nervous system infections, hypoxic-ischemic encephalopathy, vascular events, systemic infections, and diagnosed metabolic disorders, and pathogenic copy-number variants were identified using array-based comparative genomic hybridization (CGH).","12 Months",{"count":224,"type":21},2000,"Genetic diagnosis for neonates suffering from epilepsy has important implications for treatment, prognosis, and development of precision medicine strategies. Investigator performed exome sequencing (ES) or targeted sequencing on neonates with seizure onset within the first month of life. Investigator subgrouped our patients based on the onset age of seizure into neonatal and before 1 year (1-12 months), to compare the clinical and genetic features and treatment strategies.",[25,117,227,228],"Seizure Newborn","Seizure Generalized",[180],"2026-03-13",{"date":232,"type":34},"2026-03-16",{"date":234,"type":34},"2016-08-08",{"date":236,"type":21},"2026-12-30",{"name":238,"class":41},"Children's Hospital of Fudan University",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":75,"phases":249,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":101},"100550106","phase-3-short-versus-long-term-levetiracetam-in-brain-tumors-100550106","NCT06442748","Short Versus Long-term Levetiracetam in Brain Tumors","Short Versus Long-term Levetiracetam in Brain Tumors: A Phase 3 Randomized Controlled Trial (LIBRA)","LIBRA","Inclusion Criteria: • Age ≥ 18years\n\n* History of seizure\n* Histological diagnosis of primary brain tumor\n* Supratentorial location of primary tumor\n* Controlled on levetiracetam monotherapy for 6 months\n* Index surgery within 1 year\n* Karnofsky Performance Scale (KPS) ≥ 50\n\nExclusion Criteria:\n\n* KPS \\\u003C 50\n* No history of seizure\n* Unclear history of seizure episodes in the past\n* Use of antiepileptics other than levetiracetam in the previous 6 months\n* No histological diagnosis\n* Progressive disease\n* Brain metastasis\n* Altered mental status with deficits in understanding or inability to consent to the study",{"count":248,"type":21},604,[250],"PHASE3","Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in the initial few months of levetiracetam, the chance of further seizures is relatively low. The optimal duration to give levetiracetam is not well defined for these patients, and currently as standard treatment levetiracetam is continued for 2-3 years. This study aims to answer this question by comparing patients on a short course of levetiracetam (experimental arm) versus a longer course of levetiracetam (standard arm), with the anticipation that a shorter duration of treatment will not lead to increased seizure episodes.",[25,253,254,255],"Brain Tumors","Antiepileptics","Levetiracetam","2026-02-11",{"date":258,"type":34},"2026-02-13",{"date":260,"type":34},"2024-07-04",{"date":262,"type":21},"2031-06-01",{"name":264,"class":41},"Tata Memorial Centre",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":16,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":75,"phases":276,"briefSummary":277,"conditions":278,"keywords":287,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":311},"100610985","phase-3-levetiracetam-to-prevent-seizures-in-symptomatic-alzheimers-disease-in-adults-with-down-syndrome-100610985","NCT07234695","LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).","LESS-AD","Inclusion Criteria:\n\n* Diagnosed with Down Syndrome (DS), either with a karyotype or a compatible typical phenotype.\n* Age over 40 years at time of screening.\n* Symptomatic Alzheimer's Disease (AD) dementia, based on change in functionality and neuropsychological tests' results. Different cut-off points will be established to diagnose dementia depending on the level of intellectual disability of the individual, according to previous experience (Benejam et al; 2020): in adults with mild intellectual disability, a CAMCOG-DS score of 80 and an mCRT score of 29 will be chosen, whereas values of 56 and 28, respectively, will be used in subjects with moderate intellectual disability. Doubtful cases (e.g., with compromised functionality, but without alteration in the neuropsychological assessment) or those unable to complete the evaluation will be categorized by consensus among expert clinicians, using all available clinical information.\n* Willing and able caregiver who has daily contact with the study subject.\n* Subjects and caregivers must be able to comply with the prescribed regimen of study treatment throughout the course of the study and meet a minimum required time commitment of biannual in-person visits.\n* Any concurrent treatment for AD approved by the European Medicines Agency (EMA) must be stable for at least 30 days prior to screening and at least 60 days prior to study day 1. Other medications (except for those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to screening.\n* Subjects and\u002For their caregivers must be able to provide their consent before participating in any study-related procedures.\n\nExclusion Criteria:\n\n* Cognitive changes attributable to causes other than AD (for example, but not limited to, uncorrected visual or hearing deficit, severe, untreated sleep apnea or uncontrolled thyroid disorders).\n* Previous history of adult-onset epileptic seizures (over 18 years old).\n* Treatment with any kind of antiepileptic drugs, benzodiazepines, narcotics.\n* Significant comorbidities or analytical abnormalities, such as:\n* Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of the study (eg, moderate and\u002For severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.\n* Severe renal dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin), which would affect serum levetiracetam levels, or any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse effect.\n* Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks \\[TIAs\\]).\n* Significant risk of suicide, defined using the C-SSRS as the subject answering \"yes\" to suicidal ideation questions 4 or 5 or answering \"yes\" to suicidal behavior within the past 12 months.\n* Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.\n* Participation in another clinical trial within 3 months of screening.\n* Hypersensitivity to the active ingredient, other pyrrolidone derivatives, or any of the excipients\n* Pregnant and breastfeeding patients","40 Years",{"count":275,"type":21},120,[250],"The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.\n\nPatients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.\n\nBoth groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.",[279,280,281,282,283,284,285,286,54,25],"Down Syndrome","Down Syndrome (DS)","Down Syndrome (Trisomy 21)","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Alzheimer Disease (AD)","Alzheimer Blood Biomarkers",[288,289,290,291,181,292,293,294,295,296,297,298,299,300,301],"Down syndrome","epilepsy","Alzheimer","dementia","prevention","placebo-controlled","epileptic seizures","Alzheimer's disease markers","phase III","randomized","double-blind","bilateral tonic-clonic seizure","217-pTau","NfL","2026-01-08",{"date":304,"type":34},"2026-01-12",{"date":306,"type":21},"2025-12-22",{"date":308,"type":21},"2028-07",{"name":310,"class":41},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",5,{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":16,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100614039","clinical-profile-and-outcomes-of-neonatal-convulsions-in-the-neonatal-intensive-care-unit-at-assiut-university-childrens-hospital-100614039","NCT07274410","Clinical Profile And Outcomes Of Neonatal Convulsions In The Neonatal Intensive Care Unit At Assiut University Children's Hospital","Clinical Profile And Outcome Of Neonatal Convulsions Among Newborns Admitted To The Neonatal Intensive Care Unit At Assiut University Children's Hospital: A Prospective Cohort Study","Inclusion Criteria:\n\n* Children aged between 0 to 30day.\n* Children diagnosed with neonatal seizures\n* All newborn fullterm,preterm.males and females with neonatal convulsions.\n\nExclusion Criteria:\n\n* Children above age of 30 day and those with mimic condition as\n* jitteriness, benign neonatal sleep myoclonus, motor automatisms,\n* hyperekplexia, and Sandifer syndrome..","1 Day","30 Days",{"count":322,"type":21},139,"Neonatal convulsions are seizures that occur during the first 28 days of a newborn's life. They are considered a medical emergency and often indicate an underlying problem in the brain, such as lack of oxygen at birth, infections, metabolic disturbances, or structural abnormalities. Many seizures in newborns are subtle and difficult to detect without careful clinical assessment.\n\nThis study aims to determine how often neonatal convulsions occur among newborns admitted to the Neonatal Intensive Care Unit (NICU) at Assiut University Children Hospital. It will describe how affected newborns present clinically, identify the main causes, and evaluate the early outcomes during hospitalization.\n\nThe study is designed as a prospective cohort study. Newborns aged 0-30 days who are diagnosed with neonatal convulsions will be enrolled and followed throughout their stay in the NICU. Each patient will undergo full clinical evaluation and standard laboratory and imaging investigations, including blood tests, neuroimaging, and other tests as clinically indicated.\n\nThe findings of this study will provide updated local data on the incidence, causes, and outcomes of neonatal convulsions in our region. This information may help improve early diagnosis, guide appropriate treatment, and enhance the quality of neonatal care.",[325,326,25],"Neonatal Convulsions","Newborn Seizure Disorders",[328,329,330],"Neonatal convulsions","Neonatal ICU","outcomes","2025-11-28",{"date":333,"type":34},"2025-12-10",{"date":335,"type":21},"2025-12-01",{"date":337,"type":21},"2027-01-01",{"name":339,"class":41},"Assiut University",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":75,"phases":350,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":42},"100303686","modulating-movement-intention-via-cortical-stimulation-100303686","NCT03233399","Modulating Movement Intention Via Cortical Stimulation","Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures","Inclusion Criteria:\n\n(Healthy Controls)\n\n* Fluent in English\n\n(Patients with PMD or PNES):\n\n* Diagnosis of PMD\u002FPNES confirmed by a neurologist with expertise in movement disorders.\n* Per the treating neurologist, subject is unlikely to require treatment and\u002For dosage changes for 3-6 months following screening\n\nExclusion Criteria:\n\n* Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI\n* Chronic or progressive medical condition\n* Any history of traumatic brain injury or significant head trauma\n* Currently meets criteria for substance abuse or dependence\n* History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation\n* Pregnancy\n* Metal or devices in the head, including neurostimulators or metal foreign bodies\n* Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.\n* Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).\n* Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under \"strong potential hazard\" list in Rossi et al., 2009\n* Current diagnosis of any inflammatory or autoimmune disorder within last 6 months\n\nPMD and PNES Patients\n\n* Any history of traumatic brain injury or significant head trauma\n* Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;\n* Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);\n* Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months\n* Metal or devices in the head, including neurostimulators or metal foreign bodies\n* Taking tricyclic antidepressant medications or CNS active drugs under \"strong potential hazard\" list in Rossi et al., 2009;\n* Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;\n* Recurrent visual hallucinations, within the past 6 months;\n* History of significant uncontrollable movements of the head;\n* Any clinically significant abnormality on vital signs","65 Years",{"count":349,"type":21},30,[351],"NA","The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.",[25,117,354],"Psychogenic Movement Disorder",[356,357,358],"Electroencephalography","Magnetoencephalography","Transcranial Magnetic Stimulation","2025-11-25",{"date":331,"type":34},{"date":362,"type":34},"2017-07-20",{"date":364,"type":21},"2027-05",{"name":366,"class":41},"NYU Langone Health",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":16,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":75,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":42},"100499557","acute-effects-of-focused-ultrasound-modulation-on-eeg-behavior-in-status-epilepticus-patients-100499557","NCT05784805","Acute Effects of Focused Ultrasound Modulation on EEG Behavior in Status Epilepticus Patients","Inclusion Criteria:\n\n* Subjects diagnosed with ongoing NCSE or FMSE despite treatment with at least 2 ASMs\n* Provision of signed and dated informed consent form obtained from the next-of-kin\u002Flegally authorized representative\n* Treated in the ICU while monitored with continuous scalp EEG electrodes\n\nExclusion Criteria:\n\n* Unable to obtain informed consent\n* Presence of an implanted cranial neuromodulation device for treatment of epilepsy\n* Pregnancy\n* Treatment with another investigational drug or other intervention within 24 hr\n* Presence of burr hole(s) or craniotomy\n* Subjects with ferromagnetic materials in the head\n* Subjects with a TENS unit","19 Years","85 Years",{"count":376,"type":21},10,[351],"In this study, the investigators propose Pulsed Low-Intensity Focused Ultrasound (PLIFU) stimulation of brain regions that modulate (thalamus) or generate focal motor seizures (primary motor cortex), with the goal of ameliorating seizure activity in subjects in non-convulsive or focal motor status epilepticus. The course of treatment will consist of an initial 10 minute PLIFU treatment session with an option for a 2nd session if necessary.\n\nThe primary objective of this study is to determine whether PLIFU reduces or suppresses epileptic activity in patients with Non-Convulsive Status Epilepticus (NCSE)\u002FFocal Motor Status Epilepticus (FMSE) that have not responded to standard of care.",[25],"2025-10-27",{"date":382,"type":34},"2025-10-29",{"date":384,"type":34},"2023-06-24",{"date":386,"type":21},"2026-02",{"name":388,"class":41},"Yale University",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":75,"phases":398,"briefSummary":399,"conditions":400,"keywords":401,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":101},"100562055","ear-seizure-detection-earsd-study-100562055","NCT06598189","Ear-Seizure Detection (EarSD) Study","Real-time Seizure Detection, Classification, and Prediction Using a Low-Cost Low-Burden Ear-worn System","EarSD001","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients admitted to UMass Memorial Epilepsy Monitoring Unit (EMU) for long term video-EEG monitoring as part of standard care of both focal and generalized epilepsy.\n3. Willing to wear the wearable device.\n4. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Subjects wearing other ear devices such as hearing aids.\n2. Inability or unwillingness to provide informed consent.\n3. Irritation of the skin where the device is to be placed.\n4. Patients with intracranial electrodes placement.\n5. Prisoners\n6. Cognitive impaired individuals\n7. Pregnant Women\n8. Children (Age 0-17)",{"count":74,"type":21},[351],"The proposed study is an investigator-initiated study that aims to measure the accuracy of a wearable seizure detection and prediction device (Ear-Seizure Detection Device (EarSD)) by simultaneous recording with conventional video-EEG (Electroencephalogram) on patients with epileptic seizures in the Epilepsy Monitoring Unit of the hospital.",[25,54],[402,403,404],"Seizure Detection","Central Nervous System Diseases","Nervous System Diseases","2025-10-24",{"date":407,"type":34},"2025-10-28",{"date":409,"type":34},"2025-04-03",{"date":411,"type":21},"2032-12",{"name":413,"class":41},"Felicia Chu",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":421,"targetDuration":422,"studyType":22,"phases":4,"briefSummary":423,"conditions":424,"keywords":431,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":42},"100323523","longitudinal-study-of-neurogenetic-disorders-100323523","NCT03492060","Longitudinal Study of Neurogenetic Disorders","Neurogenetic Disorders: A Longitudinal Study on Natural History and Intervention Strategies","Inclusion Criteria:\n\n* Individuals must have had whole genome\u002Fexome sequencing and have a confirmed variant in any gene.\n\nExclusion Criteria:\n\n* Subjects who cannot provide genetic confirmation of a predicted deleterious variant in any gene.",{"count":111,"type":21},"5 Years","The purpose of this study is to analyze patterns in individuals with hnRNP (and other) genetic variants, including their neurological comorbidities, other medical problems and any treatment. The investigators will maintain an ongoing database of medical data that is otherwise being collected for routine medical care. The investigators will also collect data prospectively in the form of questionnaires, neuropsychological assessments, motor assessments, and electroencephalography to examine the landscape of deleterious variants in these genes.",[425,426,427,428,25,429,430],"Neurodevelopmental Disorders","Intellectual Disability","Developmental Delay","Autism Spectrum Disorder","Hypertonia, Muscle","Hypotonia",[432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455],"Gene Variant","HNRNPA1","HNRNPA2","HNRNPB1","HNRNPC1","HNRNPC2","HNRNPD","HNRNPE1","HNRNPE2","HNRNPE3","HNRNPE4","HNRNPG","HNRNPH1","HNRNPH2","HNRNPI","HNRNPK","HNRNPL","HNRNPM","HNRNPP","HNRNPQ1","HNRNPQ2","HNRNPQ3","HNRNPR","HNRNPU",{"date":380,"type":34},{"date":458,"type":34},"2018-06-13",{"date":460,"type":21},"2030-12",{"name":462,"class":41},"Columbia University",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":75,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":42},"100497785","oxygen-toxicity-mechanisms-in-humans-100497785","NCT05761756","Oxygen Toxicity: Mechanisms in Humans","Applied Physiology of Oxygen Toxicity: Mechanisms in Humans","Inclusion Criteria:\n\n* Equal numbers of male and female\n* Non-smokers\n* Aged 18-45 years\n* Males will be required to have VO2 peak \\> or equal to mL\u002Fkg min\n* and females \\> or equal to 30 mL\u002Fkg min\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiorespiratory disease, including hypertension\n* Neuromuscular disease\n* Anemia\n* History of hemoglobinopathy, including sick cell disease and trait","45 Years",{"count":472,"type":21},62,[351],"The goal of this clinical trial is to learn about the mechanisms of oxygen toxicity in scuba divers. The main questions it aims to answer are:\n\n* How does the training of respiratory muscles affect oxygen toxicity?\n* How do environmental factors, such as sleep deprivation, the ingestion of commonly utilized medications, and chronic exposure to carbon dioxide, impact the risk of oxygen toxicity?\n* How does immersion in water affect the development of oxygen toxicity?\n\nParticipants will be asked to do the following:\n\n* Undergo a basic screening exam composed of health history, vital signs, and some respiratory function tests\n* Train their respiratory muscles at regular intervals\n* Exercise on a cycle ergometer both in dry conditions and underwater\u002Funder pressure in the context of medication, sleep deprivation, or carbon dioxide exposure\n\nResearchers will compare the performance of each subject before and after the possible interventions described above to see if there are changes in exercise performance, respiratory function, cerebral blood flow, and levels of gene expression.",[476,477,25],"Oxygen Toxicity","Hypercapnia","2025-10-21",{"date":480,"type":34},"2025-10-23",{"date":482,"type":34},"2023-11-28",{"date":484,"type":21},"2026-08-31",{"name":486,"class":41},"Duke University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":75,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":42},"100484896","early-phase-1-pharmacological-modulation-of-brain-oscillations-in-memory-processing-100484896","NCT05594017","Pharmacological Modulation of Brain Oscillations in Memory Processing","Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe","Patient inclusion criteria:\n\n1. Age 18 - 55 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n5. Body mass index between 18-35 kg\u002Fm2.\n\nPatient exclusion criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. Note that pregnant patients are excluded from undergoing iEEG generally and all patients undergo a positive screening urine test for drugs of abuse at screening: cannabinoids, cocaine, amphetamines, barbiturates, opiates not otherwise explained by their prescribed medications.\n3. History of renal insufficiency.\n4. Unstable cardiac syndrome or active cardiac symptoms.\n5. Patients with liver failure.\n6. Patients with BPH.\n7. Patients with autoimmune neuropathy.\n8. Patients with uncontrolled hyperthyroidism.\n9. Patients with a history of dementia.\n10. Patient with a history of delirium after using transdermal scopolamine.\n11. History of narrow-angle glaucoma.\n12. History of pyloric obstruction or paralytic ileus.\n13. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis.","55 Years",{"count":496,"type":21},60,[142],"The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and\u002For spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.",[54,25,145,500,147],"Memory Disorders",[502,503,504],"oscillatory changes","cholinergic antagonist","muscarinic antagonist","2025-09-29",{"date":507,"type":34},"2025-10-03",{"date":509,"type":34},"2019-08-01",{"date":511,"type":21},"2027-05-31",{"name":160,"class":41},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":16,"minAge":521,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":75,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":540},"100448582","phase-3-pediatric-dose-optimization-for-seizures-in-emergency-medical-services-100448582","NCT05121324","Pediatric Dose Optimization for Seizures in Emergency Medical Services","Pediatric Dose Optimization for Seizures in EMS (PediDOSE)","PediDOSE","Inclusion Criteria:\n\n* Witnessed by the paramedic to be actively seizing, regardless of seizure type or duration; AND\n* Under the care of a paramedic; AND\n* Transported by an EMS agency participating in the study\n\nExclusion Criteria:\n\n* A prior history of a benzodiazepine allergy; OR\n* Known or presumed pregnancy; OR\n* Severe growth restriction based on the paramedic's subjective assessment","6 Months","13 Years",{"count":524,"type":21},6700,[250],"The Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study is designed to improve how paramedics treat seizures in children on ambulances. Seizures are one of the most common reasons why people call an ambulance for a child, and paramedics typically administer midazolam to stop the seizure. One-third of children with active seizures on ambulances arrive at emergency departments still seizing. Prior research suggests that seizures on ambulances continue due to under-dosing and delayed delivery of medication. Under-dosing happens when calculation errors occur, and delayed medication delivery occurs due to the time required for dose calculation and placement of an intravenous line to give the medication. Seizures stop quickly when standardized medication doses are given as a muscular injection or a nasal spray. This research has primarily been done in adults, and evidence is needed to determine if this is effective and safe in children.\n\nPediDOSE optimizes how paramedics choose the midazolam dose by eliminating calculations and making the dose age-based. This study involves changing the seizure treatment protocols for ambulance services in 20 different cities, in a staggered and randomly-assigned manner.\n\nOne aim of PediDOSE is to determine if using age to select one of four standardized doses of midazolam and giving it as a muscular injection or nasal spray is more effective than the current calculation-based method, as measured by the number of children arriving at emergency departments still seizing. The investigators believe that a standardized seizure protocol with age-based doses is more effective than current practice.\n\nAnother aim of PediDOSE is to determine if a standardized seizure protocol with age-based doses is just as safe as current practice, since either ongoing seizures or receiving too much midazolam can interfere with breathing. The investigators believe that a standardized seizure protocol with age-based doses is just as safe as current practice, since the seizures may stop faster and these doses are safely used in children in other healthcare settings.\n\nIf this study demonstrates that standardized, age-based midazolam dosing is equally safe and more effective in comparison to current practice, the potential impact of this study is a shift in the treatment of pediatric seizures that can be easily implemented in ambulance services across the United States and in other parts of the world.",[25],[529,530],"Child","Emergency Medical Services","2025-09-26",{"date":533,"type":34},"2025-09-30",{"date":535,"type":34},"2022-08-08",{"date":537,"type":21},"2026-09-30",{"name":539,"class":41},"Stanford University",20,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":551,"conditions":552,"keywords":556,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":42},"100272335","genetic-markers-of-cardiovascular-disease-in-epilepsy-100272335","NCT02824822","Genetic Markers of Cardiovascular Disease in Epilepsy","Genetic Markers of Cardiovascular Diseases and the Potential Role in Sudden Unexpected Death in Epilepsy.","Inclusion Criteria:\n\n* Adults ages 18 - 50 with a diagnosis of epilepsy or seizures, or syncope or drowning or cardiac arrest or sudden death or an abnormal ECG suggestive of an arrhythmia\n* Blood-relatives (Aged 18+) of a patient with a history of epilepsy, seizure, cardiac arrest, sudden death, drowning, syncope or arrhythmia\n\nExclusion Criteria:\n\n* Those who are unable to provide written consent.\n* Prisoners (vulnerable population)\n* Seizures secondary to ischemic events\n* Traumatic brain injury resulting in seizures\n* History of cranial surgery\n* History of brain tumor","50 Years",{"count":550,"type":21},600,"Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and sudden death related disorders in patients with epilepsy.",[54,25,553,554,555],"Syncope","Channelopathy","Cardiomyopathies",[557,558,559,560,561,562,563,564,565],"Sudden Unexpected Death in Epilepsy","SUDEP","Sudden Cardiac Arrest","Sudden Cardiac Death","Sleep","Ion channel disease","Long QT syndrome","Brugada","Catecholaminergic Polymorphic Ventricular Tachycardia","2025-09-04",{"date":568,"type":34},"2025-09-08",{"date":570,"type":4},"2016-05",{"date":572,"type":21},"2031-12",{"name":574,"class":41},"Mayo Clinic",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":42},"100251491","epidemiology-study-on-neonatal-seizure-100251491","NCT02552511","Epidemiology Study on Neonatal Seizure","A Multi-Centre Epidemiology Study on Neonatal Seizure in China","Inclusion Criteria:\n\n* Age from 0\\~28 days;\n* Clinical diagnosed with seizure;\n* EEG diagnosed with seizure;\n* Parents who consent to their participation in the study;\n\nExclusion Criteria:\n\n* Parents who will not comply to the needs and the design process.","28 Days",{"count":584,"type":21},1400,"A Multicentre, observational and cohort study to get the incidence of new-onset or newly-diagnosed seizure in neonatal population. EEG will used to record the change of brain electric activity and diagnose. Other data also will be collected since first seizure until confirmed diagnosis.",[25],"2025-09-03",{"date":589,"type":34},"2025-09-05",{"date":591,"type":34},"2015-09-01",{"date":593,"type":21},"2025-12-30",{"name":238,"class":41},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":137,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":42},"100603421","seizure-identification-on-the-intensive-care-unit-icu-100603421","NCT07136298","Seizure Identification on the Intensive Care Unit (ICU)","Seizure Semiology Identification and Agreement in the Intensive Care Setting: How do Clinical Scientists Compare to Other Healthcare Professionals (Intensivists, Neurologists, ITU Nurses and Neurophysiologists) in Identifying and Interpreting Clinical Signs in Patients on the Adult Intensive Care Unit","Inclusion Criteria:\n\nStaff working at Nottingham University Hospitals (NUH) in one of the following staff groups;\n\n* Neurophysiology Scientists\u002FClinical Physiologists at Band 7 level and above,\n* Neurophysiologists who have completed the CCT in Neurophysiology with at least 1 year of Adult ICU experience.\n* members of the Neurology medical team with at least 1 years' experience of covering ITU\n* Intensivists with at least 1 year's experience working on the Adult intensive care unit\n* Nursing staff working on the Intensive care unit with at least 1 year's experience\n\nExclusion Criteria:\n\n* Staff not employed by NUH i.e. agency staff\n* Staff in other groups not mentioned above",{"count":74,"type":21},"The aim of this project is to assess the ability of different groups of National Heath Service (NHS) professionals to correctly identify clinical seizures, and distinguish them from other movements commonly seen in the ICU environment, when shown digital video recordings only.\n\nPatients on the ICU are at risk of having seizures, however also commonly make other movements, including shivering, jerking, tics and tremors. An Electroencephalogram (EEG) records the brain wave activity and can help distinguish epileptic seizures from other movements. In a study by Bendadis et al (2010), 52 video-EEGs were reviewed containing \"possible seizures\" on the ICU. They found only 27% recorded actual epileptic events, with the other 73% having a range of other movements. Malone et al (2009) studied accuracy of diagnosis of 20 video recordings of clinical episodes on the neonatal unit, comparing different staff groups. They found no significant difference between Doctors and Nurses in correctly identifying seizures, however found that accuracy of diagnosis was generally poor.\n\nClinical scientists are currently expanding their roles and responsibilities across Neurophysiology, including giving consultant-level advice on EEG investigations. EEG recordings on the ICU are often obscured by excessive, unavoidable electrical\u002Fmovement artefacts caused by equipment such ventilators and pumps, and patient factors such as position, breathing artefact and suctioning. These make the EEG difficult to interpret (Boggs 2021). Assessing the clinical signs and symptoms which we may see in ICU patients, in the absence of interpretable EEG, is an essential skill.\n\nThis study aims to assess Clinical Scientists skills at clinical interpretation, in comparison with other staff groups in the ICU setting. Staff will be asked to watch video clips of events captured in the ICU, and tell us whether they think they are seizures or not, and explain their thought process behind the decision.",[25],[606,607,608,609,610],"Intensive Care","Clinical Scientist","Neurologists","Intensivists","ITU Nurses","2025-08-14",{"date":613,"type":34},"2025-08-22",{"date":615,"type":34},"2025-03-03",{"date":617,"type":21},"2025-08-31",{"name":619,"class":41},"Nottingham University Hospitals NHS Trust",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":628,"enrollmentInfo":629,"targetDuration":4,"studyType":75,"phases":631,"briefSummary":632,"conditions":633,"keywords":636,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":660},"100598525","phase-4-early-post-traumatic-seizures-prevention-trial-e-pts-trial-100598525","NCT07072624","Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","Assessing Phenytoin and Levetiracetam Efficacy, Cost-Effectiveness, and CYP2C9\u002FSV2A Polymorphism in Early Post-Traumatic Seizures: A Multicentric Prospective Randomized Trial","E-PTS","Inclusion Criteria:\n\n1. Patients of severe blunt TBI with GCS score less than 10.\n2. Patients with GCS of more than 10 in the presence of computed tomographic imaging findings consistent with brain injury: subarachnoid hemorrhage \\[SAH\\], subdural hematoma \\[SDH\\], epidural hematoma \\[EDH\\], intracerebral hemorrhage \\[ICH\\], or diffuse axonal injury \\[DAI\\], depressed skull fracture.\n3. Patients with penetrating injury.\n\nExclusion Criteria:\n\n1. Females of childbearing age with urine pregnancy test positive.\n2. Devastating brain injury with expected or confirmed brain death within 48 hours of hospital admission,\n3. Prehospital use of anticonvulsants\n4. Development of seizures before enrolment.","70 Years",{"count":630,"type":21},1260,[77],"Rationale\u002Fgaps in existing knowledge: The prophylaxis for post-traumatic seizures (PTS) remains controversial due to a lack of class I evidence. Investigators plan to conduct a high-quality, prospective, multicentric, randomized study regarding seizure prophylaxis in traumatic brain injury (TBI) with phenytoin, levetiracetam, and the placebo in three respective treatment groups, along with the effect of drug polymorphism on seizure occurrence.\n\nNovelty: Literature is scarce regarding the ideal management of early PTS in traumatic brain injury (TBI), a major public health problem. Further, no study has evaluated the effect of genetic polymorphism on seizure occurrence in traumatic brain injury. This Multicentric study will be the first of its kind, not only in India but also globally.\n\nObjectives: To evaluate the seizure incidence \\& efficacy of the respective anti-epileptic drug in each treatment arm. Assessment of clinical \\& functional outcomes, safety profile, and cost-effectiveness in each group. Effect of genetic polymorphisms on seizure incidence among study participants Methods: A Multicentric prospective randomized placebo-controlled double-blinded clinical trial is planned. After satisfying eligibility criteria and informed consent, TBI patients will be randomly allocated into three arms 'phenytoin arm', 'levetiracetam arm', and 'placebo'. Drug polymorphism will be analyzed in all the patients using quantitative real-time PCR.\n\nExpected outcome: This study will provide high-quality evidence in PTS management and will establish the role of prophylactic anti-epileptics in PTS. This study also opens the plethora of undesignated roles of genetic polymorphism in the efficacy and safety of levetiracetam and phenytoin in traumatic brain injury patients.",[25,634,635],"Traumatic Brain Injuries","Traumatic Brain Injury (TBI) Patients",[637,638,639,640,641,642,255,643,644,645,646,647,648,649],"Post Traumatic Seizures","Early Post Traumatic Seizures","Traumatic Brain Injury","Seizure Prophylaxis","Antiepileptic drugs","Phenytoin","Placebo","Genetic polymorphism","CYP2C9","SV2A","Randomized Controlled Trial","Cost-effectiveness","Multicentric Trial","2025-08-01",{"date":652,"type":34},"2025-08-06",{"date":654,"type":34},"2025-07-23",{"date":656,"type":21},"2028-03-15",{"name":658,"class":659},"All India Institute of Medical Sciences, Jodhpur","OTHER_GOV",3,{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":16,"minAge":668,"maxAge":494,"enrollmentInfo":669,"targetDuration":4,"studyType":75,"phases":671,"briefSummary":672,"conditions":673,"keywords":675,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":686},"100456133","phase-3-investigate-efficacy-and-safety-of-carisbamate-as-adjunctive-treatment-for-seizures-associated-with-lgs-in-children-and-adults-100456133","NCT05219617","Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults","A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension","Inclusion Criteria:\n\n1. Subject must have a documented history of Lennox-Gastaut syndrome by:\n\n   1. Evidence of more than one type of seizure, of which at least one should be an atonic or tonic seizure\n   2. History of an electroencephalogram (EEG) reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow, spike and wave pattern \\\u003C3.0 Hz)\n   3. History of developmental delay\n2. Male or female subjects\n3. Subjects must be age 4-55 years at the time of consent\u002Fassent\n4. Must have been \\\u003C11 years old at the onset of LGS\n5. Subjects must have experienced at least 2 drop seizures with potential to fall (tonic, atonic, tonic-clonic) during the 4-week Baseline period preceding randomization (minimum of 4 drop seizures in the first two weeks and 4 in the last two weeks). Drop seizures are defined as a seizure involving the entire body, trunk, or head that led or could have led to a fall, injury, slumping in a chair, or hitting the subject's head on a surface. All drop seizure types must be countable (either as isolated seizures or as countable isolated seizures in a cluster).\n6. Subjects must have been receiving 1 to 4 concomitant anti-seizure medications (ASMs) at a stable dose for at least 4 weeks before Visit 1\n7. If not taking Epidiolex, subjects may take other approved cannabidiol or over the counter cannabidiol products. If taking cannabidiol other than Epidiolex, consult Medical Monitor to determine if it counts as a concomitant ASM.\n8. Dietary therapy and any CNS stimulator settings must be stable for 4 weeks prior to baseline and maintain stable regimen throughout the study. The dietary therapy and CNS stimulators are not counted as an ASM.\n9. Parents or caregivers must be able to keep accurate seizure diaries\n10. Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of birth control during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study, if able.\n11. Subject and\u002For caregiver(s)\u002Flegal representative must be willing and able to give informed assent\u002Fconsent for participation in the study\n12. Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements\n13. History of COVID-19 vaccination is permitted\n\nExclusion Criteria:\n\n1. Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation, unless there is a progressive brain tumor\n2. Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the subject's safety or study conduct\n3. Subjects who were on adrenocorticotropic hormone (ACTH) therapy in the 6 months prior to baseline\n4. Subject on dietary therapy for less than 4 weeks prior to screening visit (Visit 1) or suffers from frequent stooling\n5. Current use of felbamate with less than 18 months of continuous exposure\n6. Concomitant use of vigabatrin: subjects who took vigabatrin in the past must be discontinued for at least 5 months before Visit 1 and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test, if able.\n7. Subject who had a history of hypoxia which needed emergency resuscitation within 12 months prior to baseline\n8. Status epilepticus within 12 weeks prior to Visit 1\n9. Any clinically significant illness (including COVID-19) in the 4 weeks prior to Visit 1, as evaluated by the Investigator\n10. Subject has clinically significant abnormal laboratory values, in the investigator's opinion, at Visit 1 or time of randomization (Visit 2)\n11. Subject has a history of any serious drug-induced hypersensitivity, e.g., toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms \\[DRESS\\]) or any drug-related rash requiring hospitalization\n12. Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Responsive Neurostimulator System (RNS) or other neurostimulation for epilepsy device implanted or activated \\\u003C5 months year prior to enrollment. Stimulation parameters that have been stable for \\\u003C4 weeks, or Battery life of unit not anticipated to extend for duration of trial.\n13. Subject is pregnant, may be pregnant, lactating or planning to be pregnant\n14. Any suicidal ideation with intent, with or without a plan within 6 months before Visit 2 (i.e., answering \"Yes\" to questions 4 or 5 in the Suicidal Ideation section of the age- specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated\n15. Any suicidal behavior within 2 years before Visit 2 (i.e., answering YES to any question in the Suicidal behavior section of the age-specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated.\n16. Evidence of significant active hepatic disease. Stable elevations of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) due to concomitant medication(s) will be allowed if they are \\\u003C3 x ULN\n17. Subject with total bilirubin \\[TBL\\] \\>2 x ULN (except for Gilbert's syndrome).\n18. Active viral hepatitis (B or C) as demonstrated by positive serology at the Screening visit (Visit 1)\n19. History of positive antibody\u002Fantigen test for human immunodeficiency virus (HIV)\n20. If taking Epidiolex, subject may not use other approved cannabidiol or over the counter cannabidiol products\n21. Scheduled for epilepsy-related surgery, VNS insertion, or any other stimulators\u002Fsurgery during the projected course of the study\n22. Subject who has taken or used any investigational drug or device in the 4 weeks prior to the screening visit (Visit 1)\n23. Concomitant use of medications known to be strong inducers of cytochrome P450 (CYP3A) including, but not limited to: phenobarbital, phenytoin, carbamazepine, primidone, rifampin, troglitazone, St. John's Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin\n24. Evidence of cardiac disease, including unstable angina, myocardial infarction, within the past 2 years, uncontrolled heart failure, major arrhythmias, congenital short QT syndrome\n25. Subject with a short QTc interval (\\\u003C340 msec) or long QTc interval (\\>460 msec) as confirmed by a repeated electrocardiogram (ECG)\n26. Benzodiazepine rescue administered on average more than once a week in the month before Visit 1\n27. Previous exposure to carisbamate or sensitivity\u002Fallergy to components of the oral suspension.","4 Years",{"count":670,"type":21},252,[250],"The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).",[25,674],"Lennox Gastaut Syndrome",[25,674,87,676],"Adults","2025-07-21",{"date":679,"type":34},"2025-07-24",{"date":681,"type":34},"2022-04-28",{"date":683,"type":21},"2028-12",{"name":685,"class":100},"SK Life Science, Inc.",71,{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":548,"enrollmentInfo":694,"targetDuration":4,"studyType":75,"phases":696,"briefSummary":697,"conditions":698,"keywords":699,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":702,"lastUpdatePostDateStruct":703,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":708,"locationsCount":42},"100225753","ketogenic-therapy-effects-on-electrical-and-metabolic-abnormalities-in-epilepsy-100225753","NCT02216500","Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy","Precision Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy","Inclusion Criteria:\n\n* Patients whose physician has prescribed the ketogenic diet\n* Patients with lab tests consistent with the ability to metabolize a high fat and low carbohydrate diet\n* Patients that can be compliant with administration of the therapy and with record keeping.\n\nExclusion Criteria:\n\n* Patients with lab tests consistent with the inability to metabolize a high fat and low carbohydrate diet\n* Patients at risk of being non-compliant with administration of the therapy and with record keeping",{"count":695,"type":21},400,[351],"Approximately a fourth of children with seizures do not respond adequately to available therapy. Ketogenic therapy has a long history as treatment for intractable epilepsy, but there is no agreement concerning how it works and what is the best way to administer it. This natural history study will collect data pertaining to both questions.",[25],[700,701],"Ketogenic Therapy","Ketogenic Diet","2025-07-08",{"date":704,"type":34},"2025-07-11",{"date":706,"type":4},"2006-09",{"date":158,"type":21},{"name":709,"class":41},"University of Florida",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":714,"acronym":715,"eligibilityCriteria":716,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":717,"targetDuration":4,"studyType":75,"phases":719,"briefSummary":720,"conditions":721,"keywords":723,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":727,"completionDateStruct":729,"leadSponsor":731,"locationsCount":42},"100546956","phase-2-perampanel-for-status-epilepticus-prophylaxis-post-cardiac-arrest-100546956","NCT06401707","PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest","PROSPER","Inclusion Criteria:\n\n* Age ≥18 years old\n* Non-traumatic, out-of-hospital cardiac arrest\n* Comatose on admission - defined as not following commands\n* Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)\n* Admission to the intensive care unit at Zuckerberg San Francisco General Hospital\n\nExclusion Criteria:\n\n* Acute cerebral hemorrhage or infarction\n* Pregnancy\n* Prisoner\n* Severe kidney function impairment with creatinine clearance inferior to 30 ml\u002Fmin\n* Severe liver impairment with liver function tests five times above the upper limit of normal\n* Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest",{"count":718,"type":21},52,[171],"Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.",[722,25,55],"Heart Arrest",[724,180,28,187],"heart arrest","2025-07-02",{"date":702,"type":34},{"date":728,"type":34},"2024-05-20",{"date":730,"type":21},"2026-10-20",{"name":732,"class":41},"University of California, San Francisco",{"id":734,"slug":735,"hasResults":12,"nctId":736,"briefTitle":737,"officialTitle":737,"acronym":738,"eligibilityCriteria":739,"healthyVolunteers":137,"sex":16,"minAge":18,"maxAge":374,"enrollmentInfo":740,"targetDuration":521,"studyType":22,"phases":4,"briefSummary":741,"conditions":742,"keywords":745,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":750,"lastUpdatePostDateStruct":751,"startDateStruct":753,"completionDateStruct":755,"leadSponsor":756,"locationsCount":42},"100505681","predisposing-factors-for-post-stroke-epilepsy-100505681","NCT05864547","Predisposing Factors for Post-stroke Epilepsy","PRESTEP","Inclusion Criteria:\n\n* First time stroke patients with capacity to consent, admitted to the stroke unit at St. Olavs hospital.\n* Modified Rankin Scale (mRS) ≤ 2 before the stroke\n\nExclusion Criteria:\n\n* Previous stroke or brain surgery\n* Traumatic brain injuries\n* Neurodegenerative diseases\n* Brain tumors\n* Epilepsy before the stroke\n* Hydrocephalus\n* Aphasia\n* Serious psychiatric disorders\n* MRI incompatibility and claustrophobia",{"count":349,"type":21},"The goal of this observational study is to learn about epilepsy after a stroke (post-stroke epilepsy). The main questions it aims to answer are:\n\n* What make some patients develop epilepsy after a stroke?\n* Does sleep have an impact on the development of post-stroke epilepsy?\n\nParticipants will undergo:\n\n* Electroencephalography (EEG)\n* Magnetic resonance imaging (MRI)\n* Polysomnography (only patients)\n\nBlood tests will also be taken. The patient group will be compared to the healthy controls. Researchers will also look into medical records of stroke patients hospitalized at St. Olavs hospital and collect relevant information.",[743,744,54,25],"Post Stroke Epilepsy","Stroke",[746,747,403,748,749],"Cerebrovascular Disorders","Brain Diseases","Nervous System Disorders","Vascular Diseases","2025-06-05",{"date":752,"type":34},"2025-06-10",{"date":754,"type":34},"2023-05-08",{"date":460,"type":21},{"name":757,"class":41},"Norwegian University of Science and Technology"]